Multi-Institutional Phase II Study of S-1 Monotherapy in Advanced Gastric Cancer with Pharmacokinetic and Pharmacogenomic Evaluations
- 1 May 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 12 (5) , 543-554
Abstract
This study describes the first phase II study of S-1, a novel oral fluoropyrimidine, in a non-Japanese Asian population with advanced gastric cancer. S-1 was administered twice daily for 28 days every 6 weeks. A pharmacokinetic study was performed on day 28 of cycles 1 and 3. Genomic DNA from peripheral mononuclear cells was analyzed using a cDNA microarray-based comparative genomic hybridization (CGH) method. Thirty-one patients were initially given a dose of 35 mg/m2 twice daily (bid) (group 1); then, the protocol was amended by increasing the dose to 40 mg/m2 bid for an additional 31 patients (group 2) because of good tolerability to S-1. The overall response rate was 19.3% (95% confidence interval, 9.2%–29.5%). Over a median follow-up duration of 265 days, the median time to progression and overall survival time were 126 and 264 days, respectively. The 1-year survival rate was 34%. There was no grade 4 toxicity and the major adverse event was anemia. Pharmacokinetic parameters were similar to those of the previous Japanese reports. Microarray CGH identified 18 genes with copy number changes that were associated with hemoglobin reduction with S-1 treatment. A logistic regression analysis, integrating one clinical parameter (initial hemoglobin level) combined with three genetic copy number variations (HIST1H2BL, C10orf127, and XPNPEP2), provided a predictive model for the development of severe hemoglobin reduction. In conclusion, this study showed the feasibility of using S-1 at 35 mg/m2 bid in gastric cancer. We suggest that the pharmacogenomic markers identified in this study may be potential candidates for predicting anemia after S-1 treatment. Disclosure of potential conflicts of interest is found at the end of this article.Keywords
This publication has 35 references indexed in Scilit:
- Systemic treatment of gastric cancerEuropean Journal of Gastroenterology & Hepatology, 2004
- The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumorsAnti-Cancer Drugs, 2004
- Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinomaCancer, 2001
- Phase I Clinical and Pharmacokinetic Study of Oral S-1 in Patients With Advanced Solid TumorsJournal of Clinical Oncology, 2000
- An Early Phase II Study of Oral S-1, a Newly Developed 5-Fluorouracil Derivative for Advanced and Recurrent Gastrointestinal CancersOncology, 1999
- Gastric cancer associated with acute disseminated intravascular coagulation: successful initial treatment with weekly 24‐hour infusion of high‐dose 5‐fluorouracil and leucovorinBritish Journal of Haematology, 1998
- Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnnals of Oncology, 1997
- Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin in the Treatment of Advanced Gastric CancersOncology, 1997
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer, 1993
- A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancerCancer, 1991